Acceleron Pharma Inc

Acceleron Pharma — 35th Annual J.P. Morgan Healthcare Conference 2017

23 slides from Acceleron Pharma's conference presentation, Jan 9, 2017

  1. Slide 1: Transforming Patient Care with Breakthrough Science

    Slide 1: Transforming Patient Care with Breakthrough Science

    Transforming Patient Care with Breakthrough Science 35TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 9, 2017 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Acceleron Forward-Looking Statements This presentation contains forward-looking statements about the Company's strategy, future plans and prospects, including statements regarding the development of the Company's compounds, including sotatercept, luspatercept, dalantercept, ACE-083, ACE-2494, the Co

  3. Slide 3: Building a Fully Integrated Biopharmaceutical Company

    Slide 3: Building a Fully Integrated Biopharmaceutical Company

    Building a Fully Integrated Biopharmaceutical Company  Two ongoing Phase 3 trials  Multiple ongoing and planned Phase 2 trials Expanding Hematology Program High Value Collaboration with Celgene Deep, Diversified Pipeline  Four clinical therapeutic candidates  Candidates #5 and #6 to enter clinic

  4. Slide 4: Therapeutic Candidates Engage the Body's Ability to Rebuild and Repair Itself

    Slide 4: Therapeutic Candidates Engage the Body's Ability to Rebuild and Repair Itself

    Acceleron’s Therapeutic Candidates Engage the Body’s Ability to Rebuild and Repair Itself  Human cells and tissues have a remarkable ability to regenerate, rebuild and repair themselves  The TGF-beta superfamily of proteins can profoundly influence many of these biological processes  Leveraging >

  5. Slide 5: Building a Rich Pipeline Based on Leadership in TGF-β Biology

    Slide 5: Building a Rich Pipeline Based on Leadership in TGF-β Biology

    Building a Rich Pipeline Based on Leadership in TGF-β Biology Phase 1 Myelodysplastic Syndromes (MDS) Beta-Thalassemia FSH Muscular Dystrophy Musculoskeletal Disease (P1 Study Planned) Fibrosis Preclinical Phase 2 Phase 3 Product Hematology Luspatercept Sotatercept Dalantercept Oncology ACE-2494 Mus

  6. Slide 6: Luspatercept: Building a Blockbuster Brand

    Slide 6: Luspatercept: Building a Blockbuster Brand

    Luspatercept: Building a Blockbuster Brand

  7. Slide 7: Luspatercept's Novel Mechanism to Treat Anemia

    Slide 7: Luspatercept's Novel Mechanism to Treat Anemia

    Luspatercept’s Novel Mechanism to Treat Anemia MDS, β-Thalassemia and Myelofibrosis EPO affects early stage RBC precursors Luspatercept restores RBC’s ability to differentiate Ineffective Erythropoiesis Treatment with luspatercept High EPO levels drive proliferation But excessive TGF-β signaling inh

  8. Slide 8: Luspatercept in MDS

    Slide 8: Luspatercept in MDS

    Luspatercept in MDS Opportunity to improve patient care in multiple population segments ESA Refractory (RS+) Lower-Risk ESA Naïve (RS+ and/or RS-) ESA Ineligible (RS+) First-line Second-line Ongoing Phase 3 MDS Trial Phase 3 Lower-Risk MDS Populations First-line Expanded MDS Populations + 40,000 to

  9. Slide 9: Luspatercept Phase 3 Trial Design in Lower-Risk MDS

    Slide 9: Luspatercept Phase 3 Trial Design in Lower-Risk MDS

    Luspatercept Phase 3 Trial Design in Lower-Risk MDS Primary Endpoint  Proportion of patients that become RBC-transfusion independent (≥ 8 weeks) during the first 24 weeks Key Secondary Endpoints  Proportion of patients that become RBC-transfusion independent (≥ 8 weeks) during the first 48 weeks 

  10. Slide 10: Reduction in Transfusion Burden in Patients with Treatment

    Slide 10: Reduction in Transfusion Burden in Patients with Treatment

    Reduction in Transfusion Burden in Patients with > 3 Mo. of Treatment Phase 2 results presented at ASH 2016  61% (17/28) patients achieved RBC transfusion independence ≥ 8 weeks  85% (24/28) of patients had a clinically meaningful erythroid response (IWG HI-E) % C h a n g e i n R B C T ra n sf u s

  11. Slide 11: Luspatercept in β-Thalassemia

    Slide 11: Luspatercept in β-Thalassemia

    Luspatercept in β-Thalassemia Opportunity to improve patient care in multiple population segments One of the most common genetic diseases in the world Transfusion Dependent Phase 3 β-Thalassemia Population Non-Transfusion Dependent / Occasionally Transfused Additional Phase 2 Study Planned Expanded

  12. Slide 12: Luspatercept Phase 3 Trial Design in β-Thalassemia

    Slide 12: Luspatercept Phase 3 Trial Design in β-Thalassemia

    Luspatercept Phase 3 Trial Design in β-Thalassemia Primary Endpoint  Proportion of patients with ≥ 33% reduction in transfusion burden from weeks 13-24 compared to the 12 weeks preceding treatment Key Secondary Endpoints  Proportion of patients with ≥ 33% reduction in transfusion burden from weeks

  13. Slide 13: Reduction in Transfusion Burden in Patients in Extension Study

    Slide 13: Reduction in Transfusion Burden in Patients in Extension Study

    * 1 subject discontinued before completing 12 weeks, not shown Baseline units/12 weeks % C h an ge in R B C Units T ran sf u se d  Transfusion reduction from 12 wks pre-treatment to any 12-wk period on treatment  83% (20/24) of TD patients experienced ≥ 33% reduction in transfusion burden  71% (1

  14. Slide 14: Myelofibrosis: Luspatercept Phase 2 Trial Planned

    Slide 14: Myelofibrosis: Luspatercept Phase 2 Trial Planned

    Myelofibrosis: Luspatercept Phase 2 Trial Planned Designed to correct anemia and eliminate/reduce RBC transfusions Disease Current Treatments Scarred, fibrotic bone marrow results in multiple cytopenias, severe anemia No approved therapy for anemia in MF: RBC transfusions, ESAs, and IMiDs Essential

  15. Slide 15: Collaborating with Celgene, the Leader in Hematology

    Slide 15: Collaborating with Celgene, the Leader in Hematology

    Collaborating with Celgene, the Leader in Hematology Luspatercept Collaboration Highlights  Celgene funds 100% of development costs  Acceleron will receive tiered royalties in the low-to mid- 20% range  $185M of milestones still outstanding for regulatory and commercial achievements  Companies w

  16. Slide 16: Key Luspatercept Milestones

    Slide 16: Key Luspatercept Milestones

    Key Luspatercept Milestones  MEDALIST and BELIEVE trials fully enrolled in 2H 2017  Present topline results by year-end 2018  Continue to generate data from extension studies to show durability in response and safety  Additional results from first-line (ESA naïve) lower-risk MDS patient segment

  17. Slide 17: Neuromuscular Diseases: Unprecedented Results in Early Clinical Studies

    Slide 17: Neuromuscular Diseases: Unprecedented Results in Early Clinical Studies

    Neuromuscular Diseases: Unprecedented Results in Early Clinical Studies

  18. Slide 18: ACE-083: Targeted Intervention for Muscle Loss

    Slide 18: ACE-083: Targeted Intervention for Muscle Loss

    ACE-083 Designed to increase muscle mass and strength selectively in the muscles in which the drug is administered ACE-083: Targeted Intervention for Muscle Loss 18 Phase 1 Produced substantial dose-dependent increases in muscle volume in a Phase 1 study ‒ 9% to 15% muscle volume increases with two

  19. Slide 19: ACE-083 Targeted Muscle Therapy in FSHD

    Slide 19: ACE-083 Targeted Muscle Therapy in FSHD

    ACE-083 Targeted Muscle Therapy in FSHD 19 Weakness limits the ability to:  Feed oneself  Lift objects  Maintain hygiene Weakness  Causes foot drop  Impairs ambulation  Increases risk of falls FSHD Epidemiology • Approx. 20,000 patients in the U.S. • Disabling focal muscle loss that can be asy

  20. Slide 20: Acceleron Newsflow and Catalysts

    Slide 20: Acceleron Newsflow and Catalysts

    Acceleron Newsflow and Catalysts  Luspatercept – Complete enrollment in MEDALIST and BELIEVE Phase 3 trials in 2H 2017 – Release topline Phase 3 Results by YE 2018 – Develop clinical and regulatory strategy in first-line lower-risk MDS in 2017 – Initiate new Phase 2 trials in myelofibrosis and NTD

  21. Slide 21: Our 2020 Vision: A Fully Integrated, Leading Biopharmaceutical Company

    Slide 21: Our 2020 Vision: A Fully Integrated, Leading Biopharmaceutical Company

    APPROVALS IN 3 INDICATIONS CASH FLOW POSITIVE Acceleron in 2020 8 UNIQUE THERAPEUTIC CANDIDATES IN CLINICAL TRIALS MULTIPLE PHASE 3 STUDIES SALES AND MARKETING ORGANIZATION IN U.S. Our 2020 Vision: A Fully Integrated, Leading Biopharmaceutical Company + 21

  22. Slide 22: Key Takeaways

    Slide 22: Key Takeaways

    Key Takeaways  A valuable mix of early, mid- and late-stage assets in clinical development that will drive value in 2017 and beyond  Global partnership with Celgene in multiple late-stage anemia indications with blockbuster potential  Powerful discovery engine generating additional new candidates

  23. Slide 23: Transforming Patient Care with Breakthrough Science

    Slide 23: Transforming Patient Care with Breakthrough Science

    Transforming Patient Care with Breakthrough Science 35TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 9, 2017

Source: SEC EDGAR · 8-K filed Jan 9, 2017

More decks from Acceleron Pharma Inc